

Short Communication

The Impact of Patient Advocacy Groups on Clinical Trial Design and Implementation

Duyvendak Karakus*

Department of Nutrition and Dietetics, Istanbul Gelisim University, Turkey

**Address Correspondence to Duyvendak Karakus, Email: karakduyvenk@gmail.com*

Received: 02 September 2024; Manuscript No: JEM-24-147685; **Editor assigned:** 04 September 2024; PreQC No: JEM-24-147685 (PQ); **Reviewed:** 18 September 2024; QC No: JEM-24-147685; **Revised:** 23 September 2024; Manuscript No: JEM-24-147685 (R); **Published:** 30 September 2024; **DOI:** 10.4303/JEM/147685

Copyright © 2024 Duyvendak Karakus. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Patient Advocacy Groups (PAGs) have become vital players in the realm of clinical research, influencing various aspects of clinical trial design and implementation. These organizations, often driven by individuals with personal stakes in specific health conditions, have significantly reshaped how clinical trials are conducted, focusing on making them more patient-centered and relevant. Their impact extends from shaping research priorities to enhancing patient recruitment and ensuring the ethical conduct of trials.

Description

One of the most significant contributions of patient advocacy groups is their role in setting research priorities. Historically, clinical research has often been driven by academic interests or pharmaceutical companies' goals, which sometimes resulted in a disconnect between research efforts and patients' most pressing needs. PAGs bridge this gap by highlighting unmet needs and advocating for research that addresses these issues. For instance, advocacy groups for rare diseases frequently push for research into conditions that may otherwise be neglected due to their low prevalence. Their efforts can lead to the prioritization of trials for treatments that are highly relevant to the patient community, ensuring that research is aligned with the needs of those most affected. Patient recruitment and retention are critical challenges in clinical trials. PAGs play a crucial role in overcoming these challenges by leveraging their networks to recruit participants and provide support throughout the trial process. They help identify potential participants who may not be reached through traditional recruitment methods. By raising awareness about clinical trials within their

communities, PAGs can significantly increase participation rates. Moreover, they often provide support services, such as transportation, financial assistance, or counseling, which can help patients overcome barriers to participation and improve retention rates. Patient advocacy groups are also instrumental in shaping the design of clinical trials to make them more patient-centered. Traditional clinical trial designs often focus on clinical and biological endpoints, sometimes overlooking what matters most to patients. PAGs advocate for the inclusion of patient-reported outcomes (PROs) and quality of life measures, ensuring that trials assess aspects of health that directly impact patients' daily lives. For example, in trials for chronic diseases, PAGs might advocate for endpoints that reflect improvements in symptoms or functional status rather than solely focusing on biological markers. Additionally, PAGs provide valuable insights into trial design by contributing to protocol development. Their involvement ensures that trial procedures are feasible and acceptable to patients. This includes considerations such as the frequency of visits, the complexity of procedures, and the burden of participation. Moreover, PAGs often advocate for transparency in reporting trial results. They emphasize the importance of disseminating findings, regardless of whether the results are positive or negative [1-4].

Conclusion

Patient advocacy groups have significantly impacted the design and implementation of clinical trials by shaping research priorities, enhancing patient recruitment and retention, improving trial design, ensuring ethical conduct, and facilitating access to new treatments. Their involvement has made clinical trials more patient-centered and relevant, ultimately leading to research that better addresses the needs

of patients. As the landscape of clinical research continues to evolve, the collaboration between PAGs, researchers, and policymakers will be crucial in advancing patient-centered care and improving health outcomes.

Acknowledgement

None.

Conflict of Interest

None.

References

1. S. Federica, V. Venti, P. Pavone, Non-epileptic paroxysmal events: Clinical features and diagnostic differences with epileptic seizures. A single tertiary centre study, *Clin Neurol Neurosurg*, 207(2021):106-117.
2. R. Durrer, P. Carvalho, R. Casarin, Statins with potential to control periodontitis: From biological mechanisms to clinical studies, *J Oral Biosci*, 63(2021): 232-244.
3. Y. Chui, M. Cheng, L. Qizhou, Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapies, *Biomed Pharmacother*, 143(2021):214-218.
4. K. Soltana, L. Moore, A. Turgeon, Adherence to clinical practice guideline recommendations on low-value injury care: A multicenter retrospective cohort study, *J Value Inq*, 24(2021): 1728-1736.